Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

Laurent Garderet; Simona Iacobelli; Linda Koster; Hartmut Goldschmidt; Jan-Erik Johansson; Jean Henri Bourhis; Marta Krejci; Xavier Leleu; Michael Potter; Didier Blaise; Christian Koenecke; Christian Peschel; Jakub Radocha; Bernd Metzner; Pascal Lenain; Kerstin Schäfer-Eckart; David Pohlreich; Mariella Grasso; Denis Caillot; Herman Einsele; Marco Ladetto; Stefan Schönland; Nicolaus Kröger

doi:10.1016/j.bbmt.2018.01.035

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

Standard

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. / Garderet, Laurent; Iacobelli, Simona; Koster, Linda; Goldschmidt, Hartmut; Johansson, Jan-Erik; Bourhis, Jean Henri; Krejci, Marta; Leleu, Xavier; Potter, Michael; Blaise, Didier; Koenecke, Christian; Peschel, Christian; Radocha, Jakub; Metzner, Bernd; Lenain, Pascal; Schäfer-Eckart, Kerstin; Pohlreich, David; Grasso, Mariella; Caillot, Denis; Einsele, Herman; Ladetto, Marco; Schönland, Stefan; Kröger, Nicolaus.

in: BIOL BLOOD MARROW TR, Jahrgang 24, Nr. 7, 07.2018, S. 1372-1378.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Garderet, L, Iacobelli, S, Koster, L, Goldschmidt, H, Johansson, J-E, Bourhis, JH, Krejci, M, Leleu, X, Potter, M, Blaise, D, Koenecke, C, Peschel, C, Radocha, J, Metzner, B, Lenain, P, Schäfer-Eckart, K, Pohlreich, D, Grasso, M, Caillot, D, Einsele, H, Ladetto, M, Schönland, S & Kröger, N 2018, 'Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma', BIOL BLOOD MARROW TR, Jg. 24, Nr. 7, S. 1372-1378. https://doi.org/10.1016/j.bbmt.2018.01.035

APA

Garderet, L., Iacobelli, S., Koster, L., Goldschmidt, H., Johansson, J-E., Bourhis, J. H., Krejci, M., Leleu, X., Potter, M., Blaise, D., Koenecke, C., Peschel, C., Radocha, J., Metzner, B., Lenain, P., Schäfer-Eckart, K., Pohlreich, D., Grasso, M., Caillot, D., ... Kröger, N. (2018). Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. BIOL BLOOD MARROW TR, 24(7), 1372-1378. https://doi.org/10.1016/j.bbmt.2018.01.035

Vancouver

Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson J-E, Bourhis JH et al. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. BIOL BLOOD MARROW TR. 2018 Jul;24(7):1372-1378. https://doi.org/10.1016/j.bbmt.2018.01.035

Bibtex

@article{a61dd098ffc3480f96ab9d50126772ff,

title = "Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma",

abstract = "To evaluate the outcomes of salvage third autologous stem cell transplantation (ASCT) in patients with relapsed multiple myeloma. We analyzed 570 patients who had undergone a third ASCT between 1997 and 2010 (European Society for Blood and Marrow Transplantation data), of whom 482 patients underwent tandem ASCT and a third ASCT at first relapse (AARA group) and 88 patients underwent an upfront ASCT with second and third transplantations after subsequent relapses (ARARA group). With a median follow-up after salvage third ASCT of 61 months in the AARA group and 48 months in the ARARA group, the day +100 nonrelapse mortality in the 2 groups was 4% and 7%, the incidence of second primary malignancy was 6% and 7%, the median progression-free survival was 13 and 8 months, and median overall survival (OS) was 33 and 15 months. In the AARA group, according to the relapse-free interval (RFI) from the second ASCT, the median OS after the third ASCT was 17 months if the RFI was <18 months, 37 months if the RFI was between 18 and 36 months, and 64 months if the RFI was ≥36 months (P < .001). In the ARARA group, the median OS after the third ASCT was 7 months if the RFI was <6 months, 13 months if the RFI was between 6 and 18 months, and 27 months if the RFI was ≥18 months (P < .001). In a multivariate analysis of the AARA group, the favorable prognostic factor was an RFI after second ASCT of ≥18 months. Progressive disease and a Karnofsky Performance Status score of <70 at third ASCT were unfavorable factors. A salvage third ASCT is of value for patients with relapsed myeloma, particularly for those with a long duration of response and chemosensitive disease at the time of transplantation.",

keywords = "Journal Article",

author = "Laurent Garderet and Simona Iacobelli and Linda Koster and Hartmut Goldschmidt and Jan-Erik Johansson and Bourhis, {Jean Henri} and Marta Krejci and Xavier Leleu and Michael Potter and Didier Blaise and Christian Koenecke and Christian Peschel and Jakub Radocha and Bernd Metzner and Pascal Lenain and Kerstin Sch{\"a}fer-Eckart and David Pohlreich and Mariella Grasso and Denis Caillot and Herman Einsele and Marco Ladetto and Stefan Sch{\"o}nland and Nicolaus Kr{\"o}ger",

year = "2018",

month = jul,

doi = "10.1016/j.bbmt.2018.01.035",

language = "English",

volume = "24",

pages = "1372--1378",

journal = "BIOL BLOOD MARROW TR",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "7",

}

RIS

TY - JOUR

T1 - Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

AU - Garderet, Laurent

AU - Iacobelli, Simona

AU - Koster, Linda

AU - Goldschmidt, Hartmut

AU - Johansson, Jan-Erik

AU - Bourhis, Jean Henri

AU - Krejci, Marta

AU - Leleu, Xavier

AU - Potter, Michael

AU - Blaise, Didier

AU - Koenecke, Christian

AU - Peschel, Christian

AU - Radocha, Jakub

AU - Metzner, Bernd

AU - Lenain, Pascal

AU - Schäfer-Eckart, Kerstin

AU - Pohlreich, David

AU - Grasso, Mariella

AU - Caillot, Denis

AU - Einsele, Herman

AU - Ladetto, Marco

AU - Schönland, Stefan

AU - Kröger, Nicolaus

PY - 2018/7

Y1 - 2018/7

N2 - To evaluate the outcomes of salvage third autologous stem cell transplantation (ASCT) in patients with relapsed multiple myeloma. We analyzed 570 patients who had undergone a third ASCT between 1997 and 2010 (European Society for Blood and Marrow Transplantation data), of whom 482 patients underwent tandem ASCT and a third ASCT at first relapse (AARA group) and 88 patients underwent an upfront ASCT with second and third transplantations after subsequent relapses (ARARA group). With a median follow-up after salvage third ASCT of 61 months in the AARA group and 48 months in the ARARA group, the day +100 nonrelapse mortality in the 2 groups was 4% and 7%, the incidence of second primary malignancy was 6% and 7%, the median progression-free survival was 13 and 8 months, and median overall survival (OS) was 33 and 15 months. In the AARA group, according to the relapse-free interval (RFI) from the second ASCT, the median OS after the third ASCT was 17 months if the RFI was <18 months, 37 months if the RFI was between 18 and 36 months, and 64 months if the RFI was ≥36 months (P < .001). In the ARARA group, the median OS after the third ASCT was 7 months if the RFI was <6 months, 13 months if the RFI was between 6 and 18 months, and 27 months if the RFI was ≥18 months (P < .001). In a multivariate analysis of the AARA group, the favorable prognostic factor was an RFI after second ASCT of ≥18 months. Progressive disease and a Karnofsky Performance Status score of <70 at third ASCT were unfavorable factors. A salvage third ASCT is of value for patients with relapsed myeloma, particularly for those with a long duration of response and chemosensitive disease at the time of transplantation.

AB - To evaluate the outcomes of salvage third autologous stem cell transplantation (ASCT) in patients with relapsed multiple myeloma. We analyzed 570 patients who had undergone a third ASCT between 1997 and 2010 (European Society for Blood and Marrow Transplantation data), of whom 482 patients underwent tandem ASCT and a third ASCT at first relapse (AARA group) and 88 patients underwent an upfront ASCT with second and third transplantations after subsequent relapses (ARARA group). With a median follow-up after salvage third ASCT of 61 months in the AARA group and 48 months in the ARARA group, the day +100 nonrelapse mortality in the 2 groups was 4% and 7%, the incidence of second primary malignancy was 6% and 7%, the median progression-free survival was 13 and 8 months, and median overall survival (OS) was 33 and 15 months. In the AARA group, according to the relapse-free interval (RFI) from the second ASCT, the median OS after the third ASCT was 17 months if the RFI was <18 months, 37 months if the RFI was between 18 and 36 months, and 64 months if the RFI was ≥36 months (P < .001). In the ARARA group, the median OS after the third ASCT was 7 months if the RFI was <6 months, 13 months if the RFI was between 6 and 18 months, and 27 months if the RFI was ≥18 months (P < .001). In a multivariate analysis of the AARA group, the favorable prognostic factor was an RFI after second ASCT of ≥18 months. Progressive disease and a Karnofsky Performance Status score of <70 at third ASCT were unfavorable factors. A salvage third ASCT is of value for patients with relapsed myeloma, particularly for those with a long duration of response and chemosensitive disease at the time of transplantation.

KW - Journal Article

U2 - 10.1016/j.bbmt.2018.01.035

DO - 10.1016/j.bbmt.2018.01.035

M3 - SCORING: Journal article

C2 - 29408334

VL - 24

SP - 1372

EP - 1378

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 7

ER -